Literature DB >> 12123635

Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure.

Yasuhiro Ikeda1, Yoshikazu Yonemitsu, Taiji Sakamoto, Tatsuro Ishibashi, Hikaru Ueno, Atsushi Kato, Yoshiyuki Nagai, Masayuki Fukumura, Hajime Inomata, Mamoru Hasegawa, Katsuo Sueishi.   

Abstract

To determine the usefulness of recombinant Sendai virus (SeV) for ocular gene transfer, the authors characterized SeV-mediated gene transfer to the retinal tissue of adult rats via subretinal injection. Recombinant SeV encoding the lacZ gene achieved frequent transgene expression in the retinal pigment epithelium (RPE) (mean=38.76%), while gene transfer to other retinal cells was rare. These findings are similar to those of previous reports using adenoviruses. Peak reporter gene expression of SeV in cultured RPE cells was similar to that of adenovirus at the same titer; however, SeV achieved high levels of expression after a brief vector-cell contact time, while adenovirus required over 3hr for efficient gene transfer. This finding was also observed in vivo following a brief SeV filling in the subretinal space, and may therefore provide a clinical advantage in avoiding retinal damage due to prolonged detachment. The observed SeV-mediated gene expression in the rat retina was transient. The initial phase of the decrease in luciferase activity could be prevented by daily eye drops of dexamethasone, suggesting that the corticosteroid-sensitive host reaction may affect early clearance of the virus. The late decline of transgene expression (2 weeks) was inhibited by the immunosuppressant, cyclosporin A, in a dose-dependent manner, suggesting that the cytotoxic T-lymphocyte response may be important in this phase. This work represents the first report of SeV-mediated gene transfer to ocular tissue, and identifies recombinant SeV as a new tool for studies of retinal gene transfer and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12123635     DOI: 10.1006/exer.2002.1177

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  5 in total

Review 1.  Gene therapy using stem cells.

Authors:  Erin R Burnight; Luke A Wiley; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-13       Impact factor: 6.915

2.  DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial.

Authors:  Yoshikazu Yonemitsu; Takuya Matsumoto; Hiroyuki Itoh; Jin Okazaki; Makiko Uchiyama; Kumi Yoshida; Mitsuho Onimaru; Toshihiro Onohara; Hiroyuki Inoguchi; Ryoichi Kyuragi; Mototsugu Shimokawa; Hiroshi Ban; Michiko Tanaka; Makoto Inoue; Tsugumine Shu; Mamoru Hasegawa; Yoichi Nakanishi; Yoshihiko Maehara
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

3.  Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions.

Authors:  Chad C Macarthur; Andrew Fontes; Namritha Ravinder; David Kuninger; Jasmeet Kaur; Matthew Bailey; Antje Taliana; Mohan C Vemuri; Pauline T Lieu
Journal:  Stem Cells Int       Date:  2012-03-22       Impact factor: 5.443

4.  Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions.

Authors:  Yoshikazu Kishino; Tomohisa Seki; Jun Fujita; Shinsuke Yuasa; Shugo Tohyama; Akira Kunitomi; Ryota Tabei; Kazuaki Nakajima; Marina Okada; Akinori Hirano; Hideaki Kanazawa; Keiichi Fukuda
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

5.  Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions.

Authors:  Yoshikazu Kishino; Tomohisa Seki; Shinsuke Yuasa; Jun Fujita; Keiichi Fukuda
Journal:  J Vis Exp       Date:  2015-11-11       Impact factor: 1.355

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.